Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on August 12, 2025, by Haleon Plc (LSE/NYSE: HLN), discloses transactions by Persons Discharging Managerial Responsibilities (PDMRs) in accordance with the UK Market Abuse Regulation. Haleon is a global consumer health leader with brands including Advil, Centrum, and Sensodyne.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive shareholding disclosures.
Material Changes and Transactions
On August 11, 2025, two PDMRs executed transactions under the Company's Share Reward Plan on the London Stock Exchange:
- Adrian Morris (General Counsel): Acquired 36 Partnership Shares at £3.563199 per share and received 36 Matching Shares at no cost. Total aggregated volume: 72 shares.
- Tamara Rogers (Chief Marketing Officer): Acquired 36 Partnership Shares at £3.563199 per share and received 36 Matching Shares at no cost. Total aggregated volume: 72 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the standard disclosure of PDMR transactions.
Investor Verification Checklist
- Verify the total number of shares held by Adrian Morris and Tamara Rogers post-transaction.
- Confirm the terms of the Share Reward Plan regarding Matching Shares.
- Review the current market price of Haleon ordinary shares (GB00BMX86B70) relative to the transaction price of £3.563199.